-
Something wrong with this record ?
Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic
O. Löblová,
Language English Country Great Britain
Document type Journal Article
NLK
ProQuest Central
from 2006-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2006-01-01 to 1 year ago
Health Management Database (ProQuest)
from 2006-01-01 to 1 year ago
- MeSH
- Technology Assessment, Biomedical organization & administration MeSH
- Humans MeSH
- Decision Making, Organizational * MeSH
- Interviews as Topic MeSH
- Health Policy * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
This article identifies the interests and policy positions of key health policy stakeholders regarding the creation of a health technology assessment (HTA) agency in the Czech Republic, and what considerations influenced them. Vested interests have been suggested as a factor mitigating the diffusion of HTA bodies internationally. The Czech Republic recently considered and discarded establishing an HTA agency, making it a good case for studying actors' policy positions throughout the policy debates. Findings are based on in-depth, semi-structured expert and elite interviews with 34 key Czech health policy actors, supported by document analysis and extensive triangulation. Findings show that the HTA epistemic community of 'aspiring agents' was the only actor strongly in favor of an HTA body. Payers and the medical device and diagnostics industry were against it; patients and clinicians had no clear preferences. Original decision-makers were in favor but a new minister of health opted for a simpler policy alternative to solve his need for expertise. Existing institutions, policy alternatives and the institutional design of a future HTA body influence domestic actors' preferences for or against an HTA agency. Domestic and international proponents of HTA should give serious thought to their concerns when advocating for HTA bodies.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20015913
- 003
- CZ-PrNML
- 005
- 20201119104907.0
- 007
- ta
- 008
- 201012s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1017/S174413311700024X $2 doi
- 035 __
- $a (PubMed)29108525
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Löblová, Olga $u Visiting Professor,School of Public Policy,Central European University,Budapest,Hungary.
- 245 10
- $a Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic / $c O. Löblová,
- 520 9_
- $a This article identifies the interests and policy positions of key health policy stakeholders regarding the creation of a health technology assessment (HTA) agency in the Czech Republic, and what considerations influenced them. Vested interests have been suggested as a factor mitigating the diffusion of HTA bodies internationally. The Czech Republic recently considered and discarded establishing an HTA agency, making it a good case for studying actors' policy positions throughout the policy debates. Findings are based on in-depth, semi-structured expert and elite interviews with 34 key Czech health policy actors, supported by document analysis and extensive triangulation. Findings show that the HTA epistemic community of 'aspiring agents' was the only actor strongly in favor of an HTA body. Payers and the medical device and diagnostics industry were against it; patients and clinicians had no clear preferences. Original decision-makers were in favor but a new minister of health opted for a simpler policy alternative to solve his need for expertise. Existing institutions, policy alternatives and the institutional design of a future HTA body influence domestic actors' preferences for or against an HTA agency. Domestic and international proponents of HTA should give serious thought to their concerns when advocating for HTA bodies.
- 650 12
- $a rozhodování organizační $7 D003659
- 650 12
- $a zdravotní politika $7 D006291
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a rozhovory jako téma $7 D007407
- 650 _2
- $a hodnocení biomedicínských technologií $x organizace a řízení $7 D013673
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00205332 $t Health economics, policy, and law $x 1744-134X $g Roč. 13, č. 2 (2018), s. 137-161
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29108525 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201012 $b ABA008
- 991 __
- $a 20201119104904 $b ABA008
- 999 __
- $a ok $b bmc $g 1584340 $s 1106081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 13 $c 2 $d 137-161 $e 20171107 $i 1744-134X $m Health economics, policy, and law $n Health Econ Policy Law $x MED00205332
- LZP __
- $a Pubmed-20201012